Rigel Pharmaceuticals | RIGL - Kapitał Własny I Rezerwy





Kapitał Własny I Rezerwy Zmiana Data
Agenus USD -199.08M 22.15M 2026-06
Amgen USD 11.69B 2.5B 2026-06
Anika Therapeutics USD 137.28M 3.38M 2026-06
Arrowhead Research USD 465.53M 148.45M 2026-06
AstraZeneca USD 50.3B 2.96B 2026-06
BioMarin Pharmaceutical USD 6.32B 109.58M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Celldex Therapeutics USD 714.56M 258.34M 2026-06
Daiichi Sankyo JPY 1.7T 38.53B 2026-06
Eli Lilly USD 33.88B 2.68B 2026-06
Halozyme Therapeutics USD 143.54M 76.09M 2026-06
Heron Therapeutics USD 6.91M 2.23M 2026-06
Intrexon USD 43.17M 75.33M 2024-06
Ionis Pharmaceuticals USD 439.74M 51.68M 2026-06
Karyopharm Therapeutics USD -265.65M 27.28M 2026-03
Ligand Pharmaceuticals USD 967.52M 29.81M 2026-06
MacroGenics USD 42.87M 21.68M 2026-06
Neurocrine Biosciences USD 3.69B 286.2M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Regeneron Pharmaceuticals USD 31.71B 287.8M 2026-06
Rigel Pharmaceuticals USD 117.61M 35.67M 2025-09
Sangamo BioSciences USD 19.6M 14.7M 2025-06
Ultragenyx Pharmaceutical USD -291M 55M 2026-06
Veracyte USD 1.39B 44M 2026-06